{"entity":{"id":"futurechem","kind":"company","name":"FutureChem","aka":[],"tldr":"FutureChem is a South Korea-based radiopharmaceutical company running 2 late-stage cancer trials of [F-18]Florastamin in prostate cancer.","summary":"FutureChem, based in Seoul, South Korea, is a radiopharmaceutical company. FUTURECHEM is a radiopharmaceutical drug-development company specialising in PET diagnostic imaging agents for neurological and oncological conditions. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing [F-18]Florastamin in prostate cancer. The largest, NCT05004285 (Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis), plans to enrol 398 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.futurechem.co.kr"},{"label":"ClinicalTrials.gov: trials led by FutureChem","url":"https://clinicaltrials.gov/search?lead=FutureChem"}],"tags":["ctgov-sponsor"],"related":["f-18"],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"Nuclide ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seoul","country":"KR","companyType":"radiopharma","website":"https://www.futurechem.co.kr","stage":"public","investors":[],"funding":[]},"route":"/companies/futurechem/","neighbours":{"isotope":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"drug":[{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/"}],"trial":[{"id":"nct05936658","kind":"trial","name":"[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer","route":"/trials/nct05936658/"},{"id":"nct05004285","kind":"trial","name":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","route":"/trials/nct05004285/"}],"institution":[{"id":"kirams","kind":"institution","name":"Korea Institute of Radiological and Medical Sciences","route":"/institutions/kirams/"},{"id":"ksnm","kind":"institution","name":"Korean Society of Nuclear Medicine","route":"/institutions/ksnm/"}],"journal":[{"id":"nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Nuclear Medicine and Molecular Imaging","route":"/journals/nuclear-medicine-and-molecular-imaging/"}]}}